インフォメーション
2021/01/25
ペプチドやオリゴ核酸を薬効本体とする中分子医薬の製造にはクロマトグラフィー精製が必須ですが、目的物質と構造が類似した不純物の存在などにより純度や回収率が課題となっています。ワイエムシィの連続クロマトグラフィーシステムContichromは独自の連続精製プロセスで純度と回収率を両立することが可能です。
この連続クロマトグラフィーシステムContichromの開発者であるThomas Müller-Späth, Ph.Dによるオンラインセミナーを実施いたします。ぜひご参加下さい。
| 日 時 | 2021年2月25日 0：00 (AM) <日本時間> (所要時間 30-60 min) | ||
| タイトル | Continuous Purification For Peptide And Oligo Therapeutics – Removing Critical Barriers In Manufacturing – | ||
| 要 旨 |
Many chromatographic purifications of chemically synthesized therapeutics are governed by a yield-purity trade-off due to the presence of product-related impurities. The impurities partially overlap with the peak at preparative load conditions. The trade-off means that high product purity can only be achieved at the cost of yield (and vice-versa) or a recycling strategy has to be implemented. Twin-column continuous countercurrent chromatography (MCSGP process) simultaneously achieves high yield and purity through automatic internal recycling of impure side fractions. Thereby MCSGP avoids excessive peak fractionation, fraction analysis and re-chromatography. Consequently, in production scale, much fewer samples need to be analyzed by QC and release times are shortened, allowing faster project turnover. Peptide and oligonucleotide purifications are two cases where the MCSGP process has shown excellent results. Both product classes have been purified at preparative scale obtaining high yield without compromising target purity. This webinar briefly introduces the MCSGP process concept and recent results of oligonucleotide and peptide purification by countercurrent chromatography, and presents the key economic aspects for scale-up. |
||
| 言語 | 英語 | ||
【講師】
Thomas Müller-Späth, Ph.D (ChromaCon AG, Switzerland)
皆さまのご参加を心よりお待ちしております。
